Eli Lilly | Sustainability Performance
Eli Lilly and Company engages in the research and development of pharmaceuticals. The company focuses on treatments across multiple disease areas.
1876
United States
10,001+ employees
Pharmaceuticals
$10B+ in revenue
$10B+ in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#11339
Overallⓘ#2567
in United Statesⓘ#268
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsEnergy consumptionWaste ManagementWater ManagementNature and biodiversitySocial
Diversity and InclusionPay GapsHealth and SafetyExternalitiesGovernance
TargetsSDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Aligned
Laggard
Aligned
Aligned
Laggard
Intensity
Greenhouse gas intensity Scope 1, 2 (tCO₂e /$M)
Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)
Energy consumption (direct) intensity (MWh /$M)
Water consumption intensity (m³ /$M)
Waste generation intensity (tonnes /$M)
Industry Benchmark
9.0
B/M 13.9
103.7
B/M 111.2
30.1
B/M 65.5
32.5
B/M 121.5
1.9
B/M 1.1
Powered by illuminem and GIST Impact
Controversy level
- Eli Lilly and Company — US pharmaceutical major (GLP-1 Mounjaro/Zepbound tirzepatide, Trulicity dulaglutide, Verzenio abemaciclib, Taltz ixekizumab) — has faced multiple US class actions over alleged inadequate disclosure of US/global GLP-1 Mounjaro/Zepbound customer demand including the contested 2024 sustained scrutiny over US compounding pharmacy GLP-1 customer compliance and the historic 2020 USD 9.5 million US DOJ Lilly Federal Trade Commission Generic Pharma alleged kickback settlement affecting US institutional shareholders.
